R&D

Research Institute Introduction

  • Home
  • R&D
  • Research Institute Introduction
R&D
Research Institute Introduction
Innovating Health
Bridging Science
Daehan Nupharm’s research institutes consist of the Central Research Institute, Bio Research Institute, and VET Lab, working closely together based on their respective expertise.
Bio Research Institute
The Daehan Nupharm Bio Research Institute is strengthening its research capabilities through the adoption of advanced technologies and collaboration, aiming to develop globally competitive biopharmaceuticals.

In the post-COVID era, demand for treatments for various modern diseases is rapidly increasing. In response to these changes, the Bio Research Institute is leading the development of next-generation therapies to address unmet medical needs through continuous innovation and convergence. We have secured essential core technologies for next-generation biopharmaceutical R&D, including AI drug design, cell and nucleic acid therapeutics, and protein engineering, and are expanding our R&D pipeline in multiple directions. The Bio Research Institute will continue to grow as a center for developing next-generation therapies that resolve unmet medical needs through ongoing technological innovation and integration.

Research Fields
  • Peptide drug
    Peptide Drug
  • Recombinant protein drug
    Recombinant Protein Drug
  • Epigenome editing therapy
    Epigenome Editing–based Therapeutics
  • Stem cell therapy
    (Companion animals)
    Stem Cell Therapeutics
Peptide drug
Peptide Drug Research
The peptide research team is developing peptide-based therapeutics to combat infectious diseases caused by a wide range of viruses.
By targeting viral lipid membranes—found in most viruses—they are working on antiviral peptides applicable to multiple viral infections.
This therapeutic strategy of directly disrupting viral membranes represents a new approach to potential future viral epidemics.
Recombinant protein drug
Recombinant Protein Drug Research
The protein drug team conducts research based on recombinant proteins to develop new treatments.
Targeting cancer, metabolic diseases, immune disorders, dementia, and more, they discover novel drug candidates using 3D protein structures and AI technology, and carry out optimization and engineering studies.
Epigenome editing therapy
Epigenome Editing–based Therapeutics Research
The epigenome editing team is developing therapeutics that regulate gene expression without altering genetic sequences.
Epigenetic therapeutics can control the expression of disease-related genes without direct genetic mutations. Since existing approaches have limitations for infectious, metabolic, and neurological diseases, the team is working on therapies that act specifically on target genes to meet these new medical needs.
Stem cell therapy
Stem Cell Therapeutics Research
The stem cell research team aims to develop veterinary cell therapies, using technologies to manipulate and culture living cells outside the body.
To respond proactively to the rapidly growing companion animal Health market, they have established a dedicated R&D team to develop stem cell therapeutics for pets. We have entered outdoor clinical trial stages in Korea and are preparing for the nation’s first commercialized stem cell therapy for companion animals.
  • STEP 01
    Adipose Tissue
    Sampling
  • STEP 02
    Stem Cell
    Isolation
  • STEP 03
    Stem Cell
    Culture
  • STEP 04
    Nitrogen Tank
    Storage
  • STEP 05
    Administration
Research Capabilities
  • AI-based Drug Design Platform
    Technology to design optimized drug candidates for target proteins based on 3D protein structures and predictive algorithms.
  • High-throughput Candidate Screening Technology
    Establishes efficient, large-scale screening methods such as ELISA and BLI for drug candidates.
  • Biopharmaceutical Process Development Technology
    Holds optimized production and purification technologies for biopharmaceuticals across different platforms.
  • Multi-target Antibody Design Technology
    Possesses antibody design technology capable of targeting two or more molecules simultaneously.
  • Cell and Nucleic Acid Therapeutics Platforms
    Equipped with development platforms for cell-based and mRNA nucleic acid–based drugs.
Article 1 (Purpose)
These Terms and Conditions are intended to define the terms of use, rights, obligations, and responsibilities between Daehan Nupharm Co., Ltd. (hereinafter the “Company”) and users regarding all websites operated by the Company (hereinafter the “Site”) and any online contents provided through the Site (hereinafter the “Contents”).
Article 2 (Effect and Amendment of the Terms)
1. These Terms shall apply to all users (including job applicants) who wish to use the Site and its Contents, as stated at the bottom of the Site.
2. Users who access the Site or register by giving consent shall be deemed to have agreed to these Terms.
3. The Company may amend these Terms to the extent that such changes do not violate relevant laws including the Act on the Regulation of Terms and Conditions. Any amended Terms shall take effect upon notice through the Site.
4. Continued use of the Site or the Contents after such notice shall be deemed acceptance of the revised Terms.
Article 3 (Matters Not Specified in the Terms)
Any matters not specified herein shall be governed by relevant laws and regulations.
Article 4 (Obligations)
Obligations of the Company
The Site shall maintain the confidentiality of users’ personal information and use it solely for purposes within the Site, such as improving and operating services or providing new information. It shall not be transferred to any third party for any other purpose. (However, exceptions shall be made where disclosure is legally required—for example, upon a lawful request by investigative authorities or the Korea Communications Standards Commission.)

Obligations of Users and Job Applicants
1. Users must comply with these Terms, applicable laws, and all notices posted on the Site.
2. Users may not engage in profit-seeking activities using the information or Contents without prior consent from the Company. That is, information or Contents obtained from the Site may not be reproduced, modified, published, or broadcast without the Company’s prior approval.
3. Users must not alter or distribute information or Contents provided by the Site in any manner that violates public order or decency
4. Users must not infringe any intellectual property rights, including copyrights, without the Company’s consent, nor harm the reputation of the Site or third parties, or interfere with their business.
Article 5 (Service Availability)
The Site shall, in principle, be available year-round without interruption, except in cases of business or technical difficulties or other unavoidable circumstances. However, the Company may partially or fully restrict service when necessary—such as for maintenance, system failure, or service overload caused by force majeure.
Article 6 (Provision, Restriction, and Suspension of Information)
1. The administrator may, in the course of operating the Site, provide various information through channels other than the Site itself.
2. The Company may restrict or suspend service when it becomes impossible to continue providing it.
Article 7 (Disclaimer)
1. The Company shall not be liable for any failure to operate the Site or provide Contents due to policy changes, special circumstances, or force majeure.
2. The Company shall not be liable for any service interruptions or restrictions arising from causes attributable to the user.
3. The Company shall not be responsible for information posted by users; all responsibility lies with the user.
4. The Company shall not be liable for any disputes or issues between users and third parties arising through the Site.
5. The Company shall not be liable for any damages caused by the intentional acts or negligence of users or visitors arising from the Site or its Contents.
6. The Company shall not be responsible for users’ failure to gain expected benefits from the service, or for any damages resulting from their choice or use of service materials.
Article 8 (Compensation for Damages)
The Company shall not be liable for any damages incurred by users in connection with the use of the Site or its Contents.
Article 9 (Governing Law and Jurisdiction)
Any disputes or lawsuits arising between the Company and users in relation to the use of the Site and its Contents shall be subject to the jurisdiction of the court having authority over the location of the Company’s head office, and the governing law shall be the laws of the Republic of Korea.
Daehan Nupharm Co., Ltd. (hereinafter referred to as the “Company”) values customers’ personal information and complies with the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc.
Through this Privacy Policy, the Company informs you of how and for what purposes your personal information is used,
and what measures are being taken to protect your personal data.
In the event of any amendments to this Privacy Policy, the Company will notify users through website announcements (hereinafter referred to as the “Site”) or individual notices.
This policy has been effective since January 1, 2014.
Items of Personal Information Collected
The Company collects the following personal information for purposes such as job applications, consultations, inquiries, and service requests.

Collected items: name, date of birth, gender, phone number (mobile/landline), address, email, photo, educational background, occupation, career details, company name, department, position, period of employment, educational history, career history, salary, job description, projects undertaken, detailed work tasks, major achievements, reason for resignation, qualifications, family information, self-introduction, veteran status, disability status, and any personal information submitted by the user for recruitment purposes. Additionally, during service use or business processing, the following information may be automatically generated and collected:
Type of browser and operating system, visit records (IP address, access time), and cookies.
Method of collection: through the Site (general inquiries, product inquiries, partnership proposals, recruitment).
Purpose of Collecting and Using Personal Information
The Company utilizes the collected personal information for the following purposes:
Responding to various inquiries.
User management and handling of complaints or civil petitions.
Evaluation and processing of recruitment applications.
Retention and Use Period of Personal Information
In principle, personal information is destroyed without delay once the purpose of collection and use has been fulfilled.
However, if retention is required under relevant laws and regulations, the Company may retain user information for a specific period as prescribed by such laws.
Items retained: Personal information items specified above.
Legal basis for retention: Consumer protection and data management.
Retention period: 3 years.
Records related to consumer complaints or dispute resolution: 3 years (in accordance with the Act on the Consumer Protection in Electronic Commerce, etc.)
Procedures and Methods of Personal Information Destruction
In principle, the Company promptly destroys personal information once the purpose of collection and use has been achieved. The procedures and methods of destruction are as follows:
Destruction procedures: Information entered by users for purposes such as membership or application submission is transferred to a separate database (or stored separately in paper form) after the purpose has been achieved. It is retained for a certain period in accordance with internal policies and relevant laws (refer to retention and use period), and then destroyed. Personal information transferred to a separate database is not used for any purpose other than as required by law.
Destruction method: The data is deleted using a database deletion method.
Provision of Personal Information
The Company does not, in principle,
When users have given prior consent.
When required by law or when an investigative agency requests such information in accordance with legally prescribed procedures.
Entrustment of Collected Personal Information
The Company does not entrust users’ personal information to external companies without prior consent.
Should such entrustment become necessary in the future, the Company will notify users of the entrusted party and the scope of the entrusted tasks, and obtain prior consent when required.
Rights of Users and Legal Representatives, and Exercise Thereof
Users may, at any time, view or modify their registered personal information and may also request withdrawal of membership.
If you contact the Personal Information Manager in writing, by phone, or via e-mail, the Company will take prompt action.
When you request correction of an error in your personal information, the Company will not use or provide such information until the correction has been completed.
If incorrect information has already been provided to a third party, the Company will notify the third party of the correction without delay so that it may be applied.
Personal information that has been canceled or deleted at the user’s request is handled according to the “Retention and Use Period of Personal Information” policy and will not be viewed or used for any other purpose.
For users under the age of 14, their legal representative has the right to access or correct the child’s personal information and to withdraw consent to its collection and use.
Use of Cookies
Purpose of Using Cookies
Cookies are used to prevent duplicate display of pop-up notifications.
Installation, Operation, and Rejection of Cookies
Users have the option to accept or reject the installation of cookies. Accordingly, users can set their web browser options to allow all cookies, to confirm each time a cookie is stored, or to reject all cookies.
By adjusting the settings of the web browser in use, users may allow all cookies, be prompted to confirm each time a cookie is saved, or refuse the storage of all cookies.
Example of setting method (for Internet Explorer): Tools at the top of the web browser → Internet Options → Privacy tab.
Personal Information Complaint and Inquiry Service
To protect customers’ personal information and handle related complaints, the Company designates the following department and Personal Information Manager
Customer Service Department: IT Team, Management Information Division
Personal Information Manager: Park Kangwon
Phone No.: +82-31-778-2626
Email: webmaster@dhnp.co.kr

You may contact the Personal Information Manager or the responsible department regarding any inquiries or complaints related to personal information protection arising from the use of the Company’s services.
The Company will provide prompt and adequate responses to your inquiries.
For further reports or consultations concerning personal data infringement, please contact the following organizations:

1. Personal Information Infringement Report Center (www.1336.or.kr/ No area code 118)
2. Korea Internet & Security Agency, Privacy Mark Certification Committee (www.eprivacy.or.kr/+82-2-580-0533–4)
3. Supreme Prosecutors’ Office Cyber Crime Investigation Center (http://icic.sppo.go.kr/+82-2-3480-3600)
4. National Police Agency Cyber Terror Response Center (www.ctrc.go.kr/+82-2-392-0330)